Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles

Advanced Drug Delivery Reviews

Volumn 61, Issue 3, 2009, Pages 218-225

  Malyala, Padma ^a   O'Hagan, Derek T ^a   Singh, Manmohan ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Antigen; Charged particles; CpG; Immunopotentiator; Polylactide co glycolide

Indexed keywords

ANTIGEN PRESENTING CELLS; BIOCOMPATIBLE POLYESTERS; BIODEGRADABLE MICROPARTICLES; CONTROLLED RELEASE; CPG; DELIVERY SYSTEMS; DRUG DELIVERY SYSTEMS; FUTURE DIRECTIONS; GLYCOLIDE; IMMUNE CELLS; IMMUNOPOTENTIATOR; IN-VITRO; IN-VIVO; LACTIDE; MICROPARTICLES; PARTICULATE DELIVERY SYSTEMS; PARTICULATE SYSTEMS; PATHOGEN RECOGNITION; PATHOGEN-ASSOCIATED MOLECULAR PATTERNS; POLYLACTIDE-CO-GLYCOLIDE; RELATED COMPOUNDS; RESORBABLE; SPECIFIC SEQUENCES; SUTURE MATERIALS; THERAPEUTIC EFFICACIES; VIRUS-LIKE PARTICLES;

ANTIGENS; CHARGED PARTICLES; LIPOSOMES; MAMMALS; OLIGONUCLEOTIDES; PHOSPHOLIPIDS;

CONTROLLED DRUG DELIVERY;

ALUMINUM POTASSIUM SULFATE; BACTERIAL ANTIGEN; BOVINE SERUM ALBUMIN; CALCIUM PHOSPHATE; CHITOSAN; CPG OLIGODEOXYNUCLEOTIDE; GLYCOPROTEIN GP 120; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; LEISHMANIA VACCINE; MALARIA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NANOPARTICLE; OVALBUMIN; POLYGLACTIN; QS 21; VIRUS ANTIGEN;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; BIODEGRADABILITY; CONTROLLED DRUG RELEASE; DRUG ADSORPTION; DRUG POTENTIATION; HUMAN; IMMUNOGENICITY; IMMUNOPOTENTIATION; LEISHMANIA MAJOR; MICROEMULSION; MICROENCAPSULATION; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; BIOTRANSFORMATION; CPG ISLANDS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MICROSPHERES; NANOPARTICLES; NANOSTRUCTURES; OLIGODEOXYRIBONUCLEOTIDES; POLYGLACTIN 910; SOLUBILITY;

EID: 61849172399     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.12.009     Document Type: Review

References (38)

1. Heit A., Busch D.H., Wagner H., and Schmitz F. Vaccine protocols for enhanced immunogenicity of exogenous antigens. Int. J. Med. Microbiol. 298 1-2 (2008) 27-32
2. Schirmbeck R., Bohm W., Ando K., Chisari F.V., and Reimann J. Nucleic-acid vaccination primes hepatitis-b virus surface antigen-specific cytotoxic t-lymphocytes in nonresponder mice. J. Virol. 69 10 (1995) 5929-5934
3. Brewer J.M., Tetley L., Richmond J., Liew F.Y., and Alexander J. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J. Immunol. 161 8 (1998) 4000-4007
4. Akira S., and Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4 7 (2004) 499-511
5. Medzhitov R., and Janeway Jr. C.A. An ancient system of host defense. Curr. Opin. Immunol. 10 1 (1998) 12-15
6. Bendelac A., and Medzhitov R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J. Exp. Med. 195 5 (2002) F19-23
7. Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1 2 (2001) 135-145
8. Zhang X.D., Weiner C.E., Salem G.J., and AK. A comparative study of the antigen-specific immune response induced by co-delivery of CpG-PDN and antigen using fusion molecules or biodegradable microparticles. J. Pharm. Sci. 96 12 (2007) 3283-3292
9. Ketloya A.E.C. Utaiwan Srichairatanakulb, Amporn Limsalakpetchb, Kosol Yongvanitchitb, Sathit Pichyangkulb and Kiat Ruxrungthama, Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates Vet. Immunol. Immunopathol. 125 1-2 (2008) 18-30
10. Malyala P., Chesko J., Ugozzoli M., Vajdy M., Zhou F., Goodsell A., O'Hagan D T., and Singh M. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J. Pharm. Sci. 97 3 (2007) 1155-1164
11. O'Hagan D.T., Singh M., and Ulmer J.B. Microparticle-based technologies for vaccines. Methods 40 1 (2006) 10-19
12. Singh M., Kazzaz J., Ugozzoli M., Malyala P., Chesko J., and O'Hagan D.T. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr. Drug. Deliv. 3 1 (2006) 115-120
13. Singh M., Kazzaz J., Ugozzoli M., Chesko J., and O'Hagan D.T. Charged polylactide co-glycolide microparticles as antigen delivery systems. Expert Opin. Biol. Ther. 4 4 (2004) 483-491
14. Kazzaz J., Singh M., Ugozzoli M., Chesko J., Soenawan E., and O'Hagan D T. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J. Control. Release 110 3 (2006) 566-573
15. Somroop S., Tongtawe P., Chaisri U., Tapchaisri P., Chongsa-nguan M., Srimanote P., and Chaicumpa W. Traffic of antibody-secreting cells after immunization with a liposome-associated, CpG-ODN-adjuvanted oral cholera vaccine. Asian Pac. J. Allergy Immunol. 24 4 (2006) 229-238
16. Naito T., Kaneko Y., and Kozbor D. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization. J. Gen. Virol. 88 Pt 1 (2007) 61-70
17. Tafaghodi M., Jaafari M.R., and Sajadi Tabassi S.A. Nasal immunization studies using liposomes loaded with tetanus toxoid and CpG-ODN. Eur. J. Pharm. Biopharm. 64 2 (2006) 138-145
18. Gill R., and Montgomery P.C. Curr. Eye Res. 24 3 (2002) 228-233
19. Singh M., Ott G., Kazzaz J., Ugozzoli M., Briones M., Donnelly J., and O'Hagan D.T. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm. Res. 18 10 (2001) 1476-1479
20. Xie H., Gursel I., Ivins B.E., Singh M., O'Hagan D.T., Ulmer J.B., Klinman D.M., Baldrick P., Richardson D., Wheeler A.W., Aggerbeck H., Heron I., Miyamura K., Nishio S., Ito A., Murata R., and Kono R. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun. 73 2 (2005) 828-833
21. Hunter S.K., Andracki M.E., and Krieg A.M. Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. Am. J. Obstet. Gynecol. 185 5 (2001) 1174-1179
22. Kaiser-Schultz G.H., Heit A., Quintanilla-Martinez L., Hammerschmnidt F., Hess S., Jennen L., Rezaei H., Wagner H., and Schatzl H.M. Polylactide-coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self tolerance to prion protein in wild type mice and induce CD4 and CD8 T cell responses. J. Immunol. 179 5 (2007) 2297-2807
23. Martinez Gomez J.M., Fischer S., Csaba N., Kundig T.M., Merkle H.P., Gander B., and Johansen P. A protective allergy vaccine based on CpG and Protamine containing PLGA microparticles. Pharm. Res. 24 10 (2007) 1927-1935
24. Mutwiri G B.P., Soita H., and Babiuk L.A. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 26 22 (2008) 2680-2688
25. O.M. Mapletoft JW, Kovacs-Nolan J, Latimer L, Mutwiri G, Babiuk LA, van Drunen Littel-van den Hurk S, Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol. 2008 Jan;89(Pt 1):250-60 89(1) (2008) 250-260.
26. Woo SJ K.C., Park M.Y., Kim H.S., Sohn H.J., Park J.S., Kim H.J., Oh S.T., and Kim T.G. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. Cancer Sci. 99 5 (2008) 1034-1039
27. Revaz V Z.R., Moser C., Schiller J.T., Ponci F., Bobst M., and Nardelli-Haefliger D. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antivir. Res. 76 1 (2007) 75-85
28. Vandepapelière P H.Y., Moris P., Van Mechelen M., Janssens M., Koutsoukos M., Van Belle P., Clement F., Hanon E., Wettendorff M., Garçon N., and Leroux-Roels G. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26 10 (2008) 1375-1386
29. Diwan M., Elamanchili P., Cao M., and Samuel J. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr. Drug Deliv. 1 (2004) 405-412
30. Wu M S.L., Liu S., Li J., Wu K., Wang L., Shen Y., Liu K., Zheng Y., Zhang X., and Gao R. The effect of entrapment of CpG sequence with cationic PLG nanoparticles on the immune responses of mice to pig paratyphoid vaccine. J. Biomed. Eng. 22 5 (2005) 975-979
31. Badiee A J.M., Samiei A., Soroush D., and Khamesipour A. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin. Vaccine Immunol. 15 4 (2008) 668-674
32. Mullen GE A.J., Dobrescu G., Rausch K., Lambert L., Long C.A., Miles A.P., and Saul A. Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. Vaccine 25 29 (2007) 5343-5347
33. Qian F R.K., Muratova O., Zhou H., Song G., Diouf A., Lambert L., Narum D.L., Wu Y., Saul A., Miller L.H., Long C.A., and Mullen G.E. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine 26 20 (2008) 2521-2527
34. Zhao ZZ Z.H., Chen Q., Su D., Xie Z., Wang Y.Y., Yang Y., Wang Z.Z., Li J.L., Wu K.Y., Wang H.N., Meng M.J., and Gao R. Promotion of immunity of mice to Pasteurella multocida and hog cholera vaccine by pig interleukin-6 gene and CpG motifs. Comp. Immunol. Microbiol. Infect. Dis. (2008) [Feb 13] [ahead of print].
35. Zwiorek K B.C., Battiany J., Winter G., Endres S., Hartmann G., and Coester C. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm. Res. 25 3 (2008) 551-562
36. Kerkmann M L.D., Weyermann J., Marschner A., Poeck H., Wagner M., Battiany J., Zimmer A., Endres S., and Hartmann G. Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles. Oligonucleotides 16 4 (2006) 313-322
37. Borges O C.-d.-S.A., Tavares J., Santarém N., de Sousa A., Borchard G., and Junginger H.E. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur. J. Pharm. Biopharm. 69 2 (2008) 405-416
38. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., Scheffczik H., Ugozzoli M., Singh M., Kazzaz J., Montomoli E., Del Giudice G., Rappuoli R., and O'Hagan D.T. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 4 (2008) 552-561